These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
155 related items for PubMed ID: 6125670
1. Low aluminium water, desferrioxamine, and dialysis encephalopathy. Milne FJ, Sharf B, Bell PD, Meyers AM. Lancet; 1982 Aug 28; 2(8296):502. PubMed ID: 6125670 [No Abstract] [Full Text] [Related]
2. Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment. Arze RS, Parkinson IS, Cartlidge NE, Britton P, Ward MK. Lancet; 1981 Nov 14; 2(8255):1116. PubMed ID: 6118567 [No Abstract] [Full Text] [Related]
4. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Milne FJ, Sharf B, Bell P, Meyers AM. Clin Nephrol; 1983 Oct 14; 20(4):202-7. PubMed ID: 6641027 [Abstract] [Full Text] [Related]
5. Role of desferrioxamine in the treatment of dialysis encephalopathy. Ackrill P, Ralston AJ, Day JP. Kidney Int Suppl; 1986 Feb 14; 18():S104-7. PubMed ID: 3457985 [No Abstract] [Full Text] [Related]
6. The use of desferrioximine in dialysis-associated aluminium disease. Ackrill P, Day JP. Contrib Nephrol; 1993 Feb 14; 102():125-34. PubMed ID: 8416177 [No Abstract] [Full Text] [Related]
7. Critical concentrations of aluminium in water used for dialysis. Hodge KC, Day JP, O'Hara M, Ackrill P, Ralston AJ. Lancet; 1981 Oct 10; 2(8250):802-3. PubMed ID: 6116918 [No Abstract] [Full Text] [Related]
8. Aluminium: removal from water supplies. Parkinson IS, Beckett A, Ward MK, Feest TG, Hoenich N, Strong A, Kerr DN. Proc Eur Dial Transplant Assoc; 1978 Oct 10; 15():586-7. PubMed ID: 740691 [No Abstract] [Full Text] [Related]
9. EEG study on progressive dialytic encephalopathy in treatment with desferrioxamine. Luda E, Canavese C. Int J Artif Organs; 1983 Jul 10; 6(4):215-6. PubMed ID: 6629528 [No Abstract] [Full Text] [Related]
10. The EEG in progressive dialysis encephalopathy. The EEG and clinical indices of PDE in cases treated with desferrioxamine. (Part. II). Luda E, Canavese C, Rocca G. Ital J Neurol Sci; 1984 Dec 10; 5(4):375-80. PubMed ID: 6530359 [Abstract] [Full Text] [Related]
11. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine. Mudde AH, Roodvoets AP, Van Groningen K. Neth J Med; 1985 Dec 10; 28(1):6-11. PubMed ID: 3974771 [No Abstract] [Full Text] [Related]
12. [Treatment of dialysis encephalopathy with deferoxamine]. Starkstein S, Berthier M, Nogués M, Leiguarda R. Medicina (B Aires); 1986 Dec 10; 46(3):327-31. PubMed ID: 3574092 [No Abstract] [Full Text] [Related]
13. Deferoxamine use in aluminum toxicity. Lewis M, Lesniak S. ANNA J; 1986 Aug 10; 13(4):210-1. PubMed ID: 3638947 [No Abstract] [Full Text] [Related]
14. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Lillevang ST, Pedersen FB. Nephrol Dial Transplant; 1989 Aug 10; 4(7):676. PubMed ID: 2510071 [No Abstract] [Full Text] [Related]
15. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN. Lancet; 1979 Feb 24; 1(8113):406-9. PubMed ID: 84261 [Abstract] [Full Text] [Related]
16. Treatment of fracturing renal osteodystrophy by desferrioxamine. Ackrill P, Day JP, Garstang FM, Hodge KC, Metcalfe PJ, Benzo Z, Hill K, Ralston AJ, Ball J, Denton J. Proc Eur Dial Transplant Assoc; 1983 Feb 24; 19():203-7. PubMed ID: 6878234 [Abstract] [Full Text] [Related]